Armata Pharmaceuticals Files 8-K

Ticker: ARMP · Form: 8-K · Filed: Oct 22, 2025 · CIK: 921114

Armata Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyArmata Pharmaceuticals, INC. (ARMP)
Form Type8-K
Filed DateOct 22, 2025
Risk Levellow
Pages2
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing, financials

TL;DR

Armata Pharma dropped an 8-K on 10/22/25 - check financials and Reg FD updates.

AI Summary

Armata Pharmaceuticals, Inc. filed an 8-K on October 22, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as AmpliPhi Biosciences Corp and Targeted Genetics Corp, is incorporated in Washington and headquartered in Los Angeles, California.

Why It Matters

This filing provides an update on Armata Pharmaceuticals' regulatory and financial status, which is crucial for investors to understand the company's current standing.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, indicating standard corporate reporting rather than a specific event with immediate high risk.

Key Players & Entities

FAQ

What specific Regulation FD disclosures are being made in this 8-K filing?

The filing indicates 'Regulation FD Disclosure' as an item information, but the specific details of the disclosure are not provided in the provided text.

What financial statements are included with this 8-K filing?

The filing lists 'Financial Statements and Exhibits' as an item information, but the specific financial statements are not detailed in the provided text.

When was Armata Pharmaceuticals, Inc. previously known by another name?

Armata Pharmaceuticals, Inc. was formerly known as AmpliPhi Biosciences Corp, with a date of name change on February 22, 2013.

What is the Standard Industrial Classification code for Armata Pharmaceuticals, Inc.?

The SIC code for Armata Pharmaceuticals, Inc. is 2836, categorized under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

What is the IRS Employer Identification Number for Armata Pharmaceuticals, Inc.?

The IRS Employer Identification Number for Armata Pharmaceuticals, Inc. is 91-1549568.

Filing Stats: 730 words · 3 min read · ~2 pages · Grade level 10 · Accepted 2025-10-22 11:15:43

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On October 22, 2025, Armata Pharmaceuticals, Inc. (the "Company") issued a press release announcing the presentation of positive results from its recently completed Phase 2a diSArm study of AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia at IDWeek 2025 TM . The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company posted to its websitea copy of the late-breaking oralpresentation delivered on October 22, 2025 by Dr. Loren G. Miller, M.D., M.P.H., at IDWeek 2025 TM (the "IDWeek Presentation"). The IDWeek Presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information contained in the IDWeek Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission ("SEC") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, except as may be required by the federal securities laws, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure. In addition, the Company disclaims any inferences regarding the materiality of such information that may arise as a result of it furnishing such information under Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01 and the attached Exhibits 99.1 and 99.2 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and the attached Exhibit

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated October 22, 2025. 99.2 IDWeek Presentation, dated October 22, 2025. 104 Cover Page Interactive Data File (embedded within Inline XBRL document). - 2 -

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 22, 2025 Armata Pharmaceuticals, Inc. By: /s/ Deborah L. Birx Name: Deborah L. Birx, M.D. Title: Chief Executive Officer (Principal Executive Officer) - 3 -

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing